Premium
Fetal and neonatal alloimmune thrombocytopenia: current trends in diagnosis and therapy
Author(s) -
Kaplan C.,
MorelKopp M.C.,
Clemenceau S.,
Daffos F.,
Forestier F.,
Tchernia G.
Publication year - 1992
Publication title -
transfusion medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.471
H-Index - 59
eISSN - 1365-3148
pISSN - 0958-7578
DOI - 10.1111/j.1365-3148.1992.tb00168.x
Subject(s) - neonatal alloimmune thrombocytopenia , medicine , fetus , natural history , pediatrics , obstetrics , pregnancy , intensive care medicine , genetics , biology
SUMMARY. Neonatal thrombocytopenia affects 20–40% of the infants in intensive care units. The frequency of neonatal alloimmune thrombocytopenia (NAIT) is estimated at 1/1500 to 1/5000 live births. The risk of morbidity is significant with 20% neurological sequelae and the death rate is estimated at 10% of affected infants. During recent years considerable efforts have been made to prevent fetal bleeding and to avoid birth trauma, which have significantly changed the natural history of NAIT.